Blast Cell-surface and Plasma Soluble Urokinase Receptor in Acute Leukemia Patients: Relationship to Classification and Response to Therapy

Satu Mustjoki; Riitta Alitalo; Ross W. Stephens; Antti Vaheri

doi:10.1055/s-0037-1614558

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1999; 81(05): 705-710
DOI: 10.1055/s-0037-1614558

Rapid Communication

Schattauer GmbH

Blast Cell-surface and Plasma Soluble Urokinase Receptor in Acute Leukemia Patients: Relationship to Classification and Response to Therapy

Satu Mustjoki

¹From the Department of Virology, University of Helsinki

,

Riitta Alitalo

²Transplantation Laboratory, Haartman Institute, University of Helsinki,

³Department of Medicine, Division of Haematology, Helsinki University Central Hospital, Helsinki, Finland

,

Ross W. Stephens

⁴Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark

,

Antti Vaheri

¹From the Department of Virology, University of Helsinki

› Institutsangaben

Abstract

Summary

Plasminogen activation in leukemia has been less well characterized than in other malignancies. However, the increased tendency to bleeding and tissue infiltration by leukemic cells are processes in which plasminogen activation may be involved. We have examined plasma and the peripheral blood mononuclear cell fraction from 80 patients including 53 patients with newly diagnosed acute leukemia and 27 patients with other hematological disorders as well as 21 healthy controls. In 28 of 29 examined patients with acute myeloid leukemia (AML) and in two of three patients with hybrid leukemia we found urokinase receptor (uPAR) on the cell surface, while most (7/9) samples from patients with acute lymphoblastic leukemia (ALL) were negative for uPAR. The plasma mean value for soluble uPAR (suPAR) was significantly elevated in patients with AML and ALL. In AML the highest values were found in patients who had residual disease after several cycles of chemotherapy. Compared to controls the uPA antigen levels in patient plasmas were elevated and decreased along with uPAR during treatment. Our results suggest that cell surface uPAR may be a useful marker for leukemia classification and in our material a high level of plasma suPAR correlated with resistance to chemotherapy in AML.

Volltext

Referenzen

References
1 Pöllänen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells.. Adv Cancer Res 1991; 57: 273-328.
2 Tapiovaara H, Alitalo R, Vaheri A. Plasminogen activation on tumor cell surface and its involvement in human leukemia.. Adv Cancer Res 1996; 69: 101-33.
3 Bell WR. The fibrinolytic system in neoplasia.. Semin Thromb Hemostas 1996; 22 (06) 459-78.
4 Mignatti P, Tsuboi R, Robbins E, Rifkin DB. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases.. J Cell Biol 1989; 108: 671-82.
5 Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, Rosenberg S. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice.. Cancer Res 1996; 56: 2428-33.
6 Danø K, Behrendt N, Brunner N, Ellis V, Ploug M, Pyke C. The urokinase receptor: protein structure and role in plasminogen activation and cancer invasion.. Fibrinolysis 1994; 8 (01) 189-203.
7 Schmitt M, Harbeck N, Thomssen C, Wilhelm U, Magdolen V, Reuning U, Ulm K, Hofler H, Janicke F, Graeff H. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy.. Thromb Haemost 1997; 78: 285-96.
8 Foekens JA, Buessecker F, Peters HA, Krainick U, van Putten WL, Look MP, Klijn JG, Krames MD. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer.. Cancer Res 1995; 55: 1423-7.
9 Stephens RW, Tapiovaara H, Alitalo R, Reisberg T, Lymboussakis A, Myöhänen H, Vaheri A. Cell-surface plasminogen activation and leukemia.. Fibrinolysis 1992; 6 (Suppl. 04) (Suppl) 35-9.
10 Wilson EL, Jacobs P, Dowdle EB. The secretion of plasminogen activators by human myeloid leukemic cells in vitro.. Blood 1983; 61: 568-74.
11 Stephens R, Alitalo R, Tapiovaara H, Vaheri A. Production of an active urokinase by leukemia cells: A novel distinction from cell lines of solid tumors.. Leukemia Res 1988; 12: 419-22.
12 Tapiovaara H, Matikainen S, Hurme M, Vaheri A. Induction of differentiation of promyelocytic NB4 cells by retinoic acid is associated with rapid increase in urokinase activity subsequently downregulated by production of inhibitors.. Blood 1994; 83: 1883-91.
13 Mustjoki S, Tapiovaara H, Sirén V, Vaheri A. Interferons and retinoids enhance and dexamethasone suppresses urokinase-mediated plasminogen activation in promyelocytic leukemia cells.. Leukemia 1998; 12: 164-74.
14 Wilson EL, Jacobs P, Francis GE, Oliver L, Burger P, Dowdle EB. Secretion of plasminogen activators by normal bone marrow cells and leukaemic myeloid cells.. Fibrinolysis 1992; 6 (Suppl. 01) (Suppl) 77-9.
15 Wada H, Kumeda Y, Ogasawara Z, Ohiwa M, Toshihiro K, Tamaki S, Ohno T, Kageyama S, Kobayashi T, Deguchi K, Shirakawa S. Plasminogen activators and their inhibitors in leukemic cell homogenates.. Am J Hematol 1993; 42: 166-70.
16 Tapiovaara H, Alitalo R, Stephens RW, Myöhänen H, Ruutu T, Vaheri A. Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients.. Blood 1993; 82: 914-9.
17 Garcia Frade LJ, Sureda A, Torrado MC, Garcia Avello A. High plasma urokinase-type plasminogen activator levels are present in patients with acute nonlymphoblastic leukemia.. Acta Haematol 1992; 88: 7-10.
18 Plesner T, Rafkier E, Wittrup M, Johnsen H, Pyke C, Pedersen TL, Hansen NE, Danø K. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue.. Am J Clin Pathol 1994; 102: 835-41.
19 Miles LA, Plow EF. Receptor mediated binding of the fibrinolytic components, plasminogen and urokinase, to peripheral blood cells.. Thromb Haemost 1987; 58: 936-42.
20 Plesner T, Behrendt N, Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.. Stem Cells 1997; 15: 398-408.
21 Nykjaer A, Møller B, Todd III RF, Christensen T, Andreasen PA, Gliemann J, Petersen CM. Urokinase receptor. An activation antigen in human T lymphocytes.. J Immunol 1994; 152: 505-16.
22 Bianchi E, Ferrero E, Fazioli F, Mangili F, Wang J, Bender J, Blasi F, Pardi R. Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes.. J Clin Invest 1996; 98: 1133-41.
23 Reiter l, Spertini O, Kruithof E. Plasminogen activators play an essential role in extracellular-matrix invasion by lymphoblastic T cells.. Int J Cancer 1997; 70: 461-6.
24 Jardi M, Ingles-Esteve J, Burgal M, Azqueta C, Velasco F, Lopez-Pedrera C, Miles LA, Felez J. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells.. Thromb Haemost 1996; 76: 1009-19.
25 Castagnari B, Moretti S, Latorraca A, Rigolin GM, Balsamo R, Lanza F, Castoldi GL.. Flow cytometry evaluation of urokinase-type plasminogen activator receptor (uPA-R) in acute myeloid leukemia cells.. Boll Soc Ital Biol Sperim 1995; 71:: 141-7.
26 Pedersen N, Schmitt M, Rønne E, Nicoletti M, Høyer-Hansen G, Conese M, Giavazzi R, Danø K, Kuhn W, Jänicke F, Blasi F. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.. J Clin Invest 1993; 92: 2160-7.
27 Stephens RW, Pedersen A, Nielsen HJ, Hamers M, Høyer-Hansen G, Rønne E, Dybkjaer E, Danø K, Brunner N. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients.. Clin Chem 1997; 43: 1868-76.
28 Rønne E, Pappot H, Grøndahl-Hansen J, Høyer-Hansen G, Plesner T, Hansen NE, Danø K. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria.. Br J Haematol 1995; 89: 576-81.
29 Sier CFM, Stephens RW, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Dano K, Brunner N, Blasi F. The level of urokinase type plasminogen activator receptor is increased in serum of ovarian cancer patients.. Cancer Res 1998; 58: 1843-9.
30 Wahlberg K, Hoyer-Hansen G, Casslen B. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer.. Cancer Res 1998; 58: 3294-8.
31 Ploug M, Rønne E, Behrendt N, Jensen AL, Blasi F, Danø K. Cellular receptor for urokinase plasminogen activator. Carboxylterminal processing and membrane anchoring by glycosyl-phosphatidylinositol.. J Biol Chem 1991; 266: 1026-33.
32 Høyer-Hansen G, Rønne E, Solberg H, Behrendt N, Ploug M, Lund LR. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.. J Biol Chem 1992; 267: 18224-9.
33 Pappot H, Høyer-Hansen G, Rønne E, Hoi-Hansen H, Brunner N, Danø K, Grøndahl-Hansen J. Elevated levels of receptor for urokinase plasminogen activator in patients with non-small cell lung cancer.. Eur J Cancer 1997; 33: 867-72.
34 Stephens RW, Leung K-C, Pöllänen J, Salonen E-M, Vaheri A. Microplate immunocapture assay for plasminogen activators and their specific inhibitors.. J Immunol Methods 1987; 105: 245-51.
35 Wohn KD, Kanse SM, Deutsch V, Schmidt T, Eldor A, Preisner KT. The urokinase receptor (CD87) is expressed in cells of the megakaryoblastic lineage.. Thromb Haemost 1997; 77: 540-7.
36 Perez-Atayde A, Sallan S, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia.. Am J Pathol 1997; 150: 815-21.
37 Lanza F, Castoldi GL, Castagnari B, Todd II, RF I, Moretti S, Spisani S, Latorraca A, Focarile E, Roberti MG, Traniello S. Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells.. Brit J Haematol 1998; 103: 110-23.